miércoles, 7 de agosto de 2019

Pemetrexed/Carboplatin/Gefitinib: New Standard of Care for Untreated EGFR-Mutant Lung Cancer?

By: Joseph Fanelli 

Posted: Friday, July 26, 2019
The addition pemetrexed/carboplatin chemotherapy to the tyrosine kinase inhibitor gefitinib improved both progression-free and overall survival in patients with untreated EGFR-mutant non–small cell lung cancer (NSCLC)—but also led to increased levels of toxicity—according to results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9001). Vanita Noronha, MD, of the Tata Memorial Centre, Mumbai, India, and colleagues concluded that this triple regimen may represent a new standard first-line therapy in for this patient population.https://jnccn360.org/nsclc/news/pemetrexed-carboplatin-gefitinib/?utm_source=Email&utm_medium=Email&utm_campaign=JNCCN360+Emails+3.9+Ongoing&email=4429d9ae632e1e91cae2532dc2648357316e68709569c840033c7813d88e52ac#.XUuCW4rDlFA.blogger




No hay comentarios:

Publicar un comentario